TRAW press release
Key Highlights
- ➤Ratutrelvir Phase 2a: 13.5-day symptom resolution versus 14.5 days with PAXLOVID
- ➤Traws (TRAW) plans FDA registration discussions for PAXLOVID-ineligible high-risk adults
- ➤TXM tablet bridging showed comparable exposure and supported once-monthly dosing
- ➤TXM toxicology studies found no mutagenic effect; updated package due for Q4 2026 resubmission
- ➤Cash fell to $2.3 million from $3.8 million; $50 million stock facility remains unused
Expert Statements
Iain Dukes, Chief Executive Officer of Traws Pharma
“We have made meaningful progress toward our goal of developing new treatment and prevention options for patients most vulnerable to serious respiratory viral diseases. For ratutrelvir, the final Phase 2a results support its potential as a once-daily, ritonavir-free treatment option for COVID-19, particularly for patients who are ineligible for PAXLOVID(®). Our next priority is to engage the FDA on a registration strategy focused on these patients.”
Iain Dukes, Chief Executive Officer of Traws Pharma
“For tivoxavir marboxil, the tablet bridging study achieved its objectives, and toxicology retesting is complete. These results support further evaluation of TXM as a potential once-monthly oral influenza prevention option. We expect to resubmit the updated toxicology package in the fourth quarter.”
* Ratutrelvir (COVID): Positive final Phase 2a results support further studies in PAXLOVID(®)-ineligible patients * Tivoxavir marboxil (TXM, Influenza): Successful completion of tablet bridging study and toxicology retesting support a planned Q4 2026 regulatory resubmission NEWTOWN, Pa., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, “Traws Pharma,” “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies for COVID-19 and influenza, today reported financial results for the quarter ended September 30, 2026, and provided business highlights for its two antiviral programs: ratutrelvir, a once-daily, ritonavir-free oral antiviral in development for COVID-19, and tivoxavir marboxil (TXM), an investigational long-acting agent for the prevention of seasonal and pandemic influenza.
“We have made meaningful progress toward our goal of developing new treatment and prevention options for patients most vulnerable to serious respiratory viral diseases,” said Iain Dukes, MA, DPhil, Chief Executive Officer of Traws Pharma. “For ratutrelvir, the final Phase 2a results support its potential as a once-daily, ritonavir-free treatment option for COVID-19, particularly for patients who are ineligible for PAXLOVID(®). Our next priority is to engage the FDA on a registration strategy focused on these patients.”
Get started
Create a free account to read the full story.
